Beatrijs W.
- Country
- The Netherlands
- Department
- #6002:Neurology
Research Overview
- Evaluation of Imlifidase for Acute Inflammation in AQP4-IgG Associated Neuromyelitis Optica Spectrum Disorder
- Evaluation of Personalized Extended Interval Dosing of Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis
- Long-term Safety, Tolerability, and Efficacy Evaluation of Ofatumumab in Patients with Relapsing Multiple Sclerosis: An Open-label Extension Study
Data & Insights
Has run more than one trial at 2 of 121 partner sites.
Specializations
Neurological Disorders
This investigator specializes in treating multiple sclerosis, with particular emphasis on relapsing forms of the condition. Their research encompasses innovative therapeutic approaches using targeted immunomodulatory treatments.
- Relapsing Multiple Sclerosis (RMS)
- Extended Interval Treatment Protocols
- Long-term Disease Management
The investigator's work focuses on evaluating sustained therapeutic responses in neurological conditions.
Neuroimmunology
Their expertise extends to neuromyelitis optica spectrum disorder, investigating novel therapeutic interventions for acute inflammatory episodes. The research emphasizes antibody-mediated treatment approaches.
- AQP4-IgG Associated Disorders
- Acute Inflammation Management
- Antibody Depletion Strategies
The investigator explores targeted immunological interventions for neurological autoimmune conditions.
Treatment Optimization
The investigator specializes in developing personalized dosing strategies for neurological therapeutics, with particular attention to safety and efficacy optimization in real-world clinical settings.
- Personalized Medicine Approaches
- Extended Interval Dosing
- Real-life Treatment Cohorts
Their work encompasses innovative treatment protocols aimed at enhancing therapeutic outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.